The first generic copy of Roche’s top-selling flu pill Tamiflu hit the U.S. market, marking a further step in the Swiss drugmaker’s enforced evolution to reliance on a new wave of blockbuster medicines.

Rivals Novo Nordisk and Sanofi have won U.S. approval for new combination drugs to treat diabetes, sparking a fresh battle for sales in a fiercely competitive market.

Privately held drugmaker Kaleo Inc. announced plans for a U.S. relaunch of its Auvi-Q injector for life-threatening allergic reactions in the first half of 2017.

Pfizer Inc. announced it has launched a new app, Moodivator, to help motivate and encourage the millions of adults who experience depression.

AbbVie’s biologic therapy Humira for autoimmune diseases was the worldwide prescription-drug sales leader in 2015 for the fourth consecutive calendar term.

The new generation of hep C drugs has completely changed the conversation about launches.

Med Ad News’ first edition of the Pharma Leaders of Innovation special feature showcases two CEOs focusing outside the big pharma box and an agency tech leader.

Bringing its brand name to life, Fingerpaint – a marketing innovation agency as well as founding partner and sponsor of Cannes Lions Health – unveiled the first-ever Virtual Reality (VR) Fingerpaint Studio at the Cannes Lions Health Festival. Fingerpaint also launched the agency’s new Hands-On Brands movement in Cannes.

Virtus Pharmaceuticals Inc. – a specialty niche pharmaceutical company and part of the Linden Capital Partners portfolio – announced it launched Prometrium (Progesterone, USP Capsules), the company’s first branded product.

Dupilumab, Regeneron/Sanofi Dupilumab is the first systemic therapy to demonstrate positive Phase III results in patients with moderate-to-severe atopic dermatitis. The serious, chronic inflammatory skin disease is marked by widespread rash, itching and associated psychosocial comorbidities. Dupilumab inhibits interleukin-4 and interleukin-13, which are small anti-inflammatory proteins secreted by cells that are thought to play a […]